Akademik Veri Yönetim Sistemi
UNION OF THRACE UNIVERSITIES V. INTERNATIONAL HEALTH SCIENCES CONGRESS 2022, Balıkesir, Türkiye, 1 - 02 Aralık 2022, ss.14
Migraine is one of the most common chronic neurovascular
diseases worldwide. The most prominent symptoms of the disease are attacks of
moderate or severe headache, a chronic neurological disorder. Current studies
suggest that the most acute symptoms associated with migraine include
photophobia, phonophobia, cutaneous allodynia, and gastrointestinal symptoms
such as nausea and vomiting. Although many studies have been conducted on the
origin of the disease, the molecular mechanisms underlying migraine are still
not fully understood.
The transient receptor potential (TRP) vanilloid-1 (TRPV1)
channel, a member of the TRP channel family, is well characterised in the
mammalian body, expressed by a subset of peripheral sensory neurons involved in
the sensation of pain and several other neuronal and non-neuronal regions. The
literature shows that stimulation of TRPV1 causes a burning sensation
reflecting the central role of the channel in pain. Pharmacological and genetic
studies have confirmed that TRPV1 is a therapeutic target in various
preclinical chronic pain models, including cancer, neuropathic, postoperative,
and musculoskeletal pain. In addition, in vivo, experimental pain model studies
have shown that TRPV1 antagonists effectively reduce pain. Another
experimental migraine model study highlighted the TRPV1 channel's role in
nociceptive trigeminocervical signalling via the trigeminocervical complex or
neurogenic dural vasodilation. In a clinical study, 46 patients diagnosed with
migraine (27 episodic and 19 chronic) and 50 healthy individuals were in the
control group; It was concluded that TRPV1 1911A>G SNP genotyping can be
used as a prognostic factor and clinical biomarker to predict the severity of
migraine and to choose a timely prophylactic treatment strategy. In other
studies on migraine pain, it has been stated that there is an important
relationship between TRPV1 and the neuropeptides calcitonin gene-related
peptide (CGRP) and substance P (SP).
In conclusion, when examining the existing literature
data that there is an important relationship between migraine and the TRPV1
channel, it will be important to clarify the role of the TRPV1 channel in this
mechanism to understand better the molecular mechanisms related to migraine
pain. Thus, we think that the control of cell activation of the TRPV1 channel
will provide a therapeutic approach as a pharmacological target in treating
migraine.